Gut Health & Mucosal Repair Peptides

Gastrointestinal peptides are a class defined by their site of action: the gut lumen, mucosa, and enteric signaling systems. The class spans gastric-juice-derived sequences with unusual stability in the GI environment (BPC-157), minimal anti-inflammatory melanocortin fragments studied in inflammatory bowel disease models (KPV), FDA-approved intestinotrophic hormones (Teduglutide), and endogenous antimicrobial effectors of mucosal immunity (LL-37). Adjacent compounds such as Larazotide, a tight-junction modulator evaluated in celiac disease trials, share this mucosal focus. The gut is also the one compartment where orally administered peptides can act locally without surviving systemic absorption, giving this class a distinct pharmacokinetic logic.

BPC-157 is a pentadecapeptide derived from a human gastric juice protein that remains stable in gastric acid, acting through nitric oxide system modulation and angiogenesis to accelerate mucosal and deeper tissue repair in animal models. KPV, the C-terminal tripeptide of alpha-MSH, is transported into colonic epithelial cells and immune cells by the PepT1 transporter—upregulated in inflamed IBD tissue—and suppresses NF-kB-driven inflammatory signaling. Teduglutide is a DPP-4-resistant GLP-2 analog that activates the GLP-2 receptor on subepithelial myofibroblasts and enteric neurons, driving crypt cell proliferation, villus growth, and increased nutrient absorptive capacity. LL-37, the human cathelicidin, provides direct antimicrobial activity at the mucosal surface while signaling epithelial restitution through formyl peptide receptors.

Teduglutide (Gattex/Revestive) was FDA-approved in 2012 for adults with short bowel syndrome dependent on parenteral support, with a subsequent pediatric indication—it is the only peptide in this class with regulatory approval for a GI indication. BPC-157 has no completed human clinical trials and remains investigational despite extensive animal-model literature in ulcer, fistula, and colitis models. KPV has demonstrated anti-inflammatory effects in IBD animal models, including nanoparticle-formulated oral delivery studies. LL-37 has been evaluated in early-phase trials for wound and infection applications rather than primary GI indications. Larazotide reached Phase 3 celiac disease trials but did not achieve approval.

Route of administration determines what a gut peptide study actually measures: oral dosing tests luminal and mucosal effects, while systemic dosing tests effects on deeper gut wall structures and remote tissues. BPC-157's gastric stability makes genuine oral bioactivity plausible in the GI tract, but plasma pharmacokinetics remain poorly characterized. KPV is rapidly degraded in biological fluids, motivating formulation-dependent delivery strategies. LL-37 exhibits concentration-dependent cytotoxicity toward host cells, narrowing its therapeutic window. IBD animal models (TNBS, DSS colitis) are the standard preclinical systems for this class, and translational relevance to human Crohn's disease and ulcerative colitis varies by model.